South Korean firm Neurophet, specializing in brain image analysis software, raised $15 million in Series C funding with participation from KB Securities, Mirae Asset Securities, and IBK Industrial Bank of Korea. This totals their investments to $39 million since 2016. Their software identifies Alzheimer’s biomarkers in PET and MRI scans, including amyloid beta and tau proteins. With plans to release a comprehensive Alzheimer’s diagnosis support software next year, they aim to monitor ARIA, linked to anti-amyloid beta immunotherapies. Neurophet also preparing for a KOSDAQ listing. Additionally, H2U secures strategic investment in South Korea, SURGLASSES gains $6.5M for surgical navigation, and InMed.ai secures FDA clearance for brain geometry analytics software.
South Korean company Neurophet, a provider of brain image analysis software, has raised 20 billion won ($15 million) in a Series C funding round participated by institutional investors, such as KB Securities, Mirae Asset Securities, and IBK Industrial Bank of Korea.
This brings its total investments since its founding in 2016 to 50 billion won ($39 million).
Neurophet has developed software that can automatically analyze PET and MRI scans to detect biomarkers of Alzheimer’s disease, including amyloid beta protein and tau protein. The Neurophet SCALE PET can also monitor amyloid-related imaging abnormalities or ARIA, observed in patients undergoing anti–amyloid beta immunotherapies.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Along with the anticipation of more anti-amyloid beta immunotherapies coming to the market, Neurophet looks to introduce a total Alzheimer’s disease diagnosis support software, which includes ARIA monitoring, next year.
Meanwhile, Neurophet is also preparing for a public listing on the Korea Exchange’s small and medium ventures board KOSDAQ next year.
H2U secures investment, partnership in South Korea
Taiwan-based provider of corporate digital health solutions H2U has received an undisclosed strategic investment from Seoul Clinical Laboratories (SCL) Group through its affiliate company, KOSDAQ-listed medical device firm InnoTherapy.
The deal will allow H2U to introduce its corporate and personal health management solutions to the Korean market, starting with adoption across SCL Group’s health exam facilities in about 4,500 clinics nationwide. H2U, in turn, will assist the SCL Group, through another affiliate company, AhealthZ, to deliver its medical testing technology and other products in Taiwan.
SURGLASSES gets $6.5M pre-Series A funding
Another Taiwanese company, SURGLASSES, has obtained fresh funding worth $6.5 million in a recent raise. The oversubscribed pre-Series A funding round was led by Taiwania Capital and participated by Integrated Capital, 500 STARTUPS, Wisdom Capital, and Sustainable Impact Capital.
The proceeds will go to accelerating the R&D and promotion of its augmented reality-based surgical navigation system, the Caduceus S. The technology, which is designed for complex spinal surgeries, was recently cleared by the US FDA.
InMed.ai secures 510(k) for brain geometry analytics software
In-Med Prognostics (InMed.ai) has recently obtained a 510(k) clearance from the US FDA for its volumetric brain analysis software.
The NeuroShield calculates brain volumes from 3D MR scans to support the treatment of neurodegenerative diseases. It is said to be the first software of its kind to offer adjustable reference ranges for age, gender, and ethnicity.
Source: Mobihealthnews
